APRE
Aprea Thera
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 585.18M; Volume: 85.53K; AvgVol 3m: 82.79K; Beta: –;
Cost estimate:
P/E: –; EPS: 1.25; EPS growth quarter/prev quarter: -70.50%;
EPS growth this year: -64.90%; EPS growth past 5 years: ;
EPS ttm: -2.04;
P/S: ; P/B: 5.70; P/Cashflow: 5.27; P/FCF: ;
Sales: –; Sales growth quarter/prev quarter: ; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -41.90%; ROE – return on equity: -67.60%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 12.94%; Insider Transactions:-37.53%;
Institutional Ownership: 90.00%; Institutional Transactions: 0.83%;
Data update: 07/10/2020.